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ABSTRACT The release of insulin from the pancreatic ,B
cell is dependent upon a complex interplay between stinulators
and inhibitors. Recently, amylin, a peptide secreted by pan-
creatic ,B ceils, has been implicated in the development of type
II (noninsulin dependent) diabetes through its modulation of
the peripheral effects of insulin. However, the effect of amylin
on insulin secretion from the .8 cell has remained controversial.
It is reported here that in single ,B cells exhibiting normal
glucose sensing, amylin causes membrane hyperpolarization,
increases in net outward current, and reductions in insulin
secretion. In contrast, in cells with abnormal glucose sensing
(e.g., from db/db diabetic mice), amylin has no effect on
electrical activity or secretion. Thus, amylin's effects on exci-
tation-secretion coupling in the (8 cell of the pancreas appear
to be linked to the cell's capacity for normal glucose sensing.
Although the mysteries underlying the effects of glucose and
other secretagogues on pancreatic ,B-cell electrical and se-
cretory activity are rapidly unfolding, the mechanisms by
which hormones and peptides modulate these activities re-
main unclear. Certain neuropeptides, released by nerves
supplying the pancreas, decrease insulin secretion. This
inhibition involves coupling between receptors and ion chan-
nels (1). In contrast to such neurotransmitters, it is not known
whether and how peptides secreted from the ,B cells them-
selves affect insulin secretion. Amylin, a 37-aa peptide, is
colocalized with insulin in 13-cell secretory granules ofhuman
islets (2) and is cosecreted with insulin. It is also the major
component of pancreatic islet amyloid commonly found in
the pancreases of patients with non-insulin-dependent dia-
betes mellitus (3). In this disease, loss of normal glucose
sensing is one of the earliest defects. Although peripheral
actions of amylin have been demonstrated, the influence of
amylin on insulin secretion is still debated (4-7). Though the
overall role ofamylin in regulating insulin secretion and in the
development of diabetes may remain unclear for some time,
it is critical to determine the effects of amylin on stimulus-
secretion coupling at the single-cell level. Thus, we have
examined the effects of amylin on excitation and insulin
secretion in single isolated pancreatic /3 cells that exhibit
normal or abnormal glucose sensing.
METHODS
To determine the effects of both glucose and amylin on
membrane electrical parameters of single /8 cells, we used the
nystatin perforated patch technique (8) to record membrane
potentials and ion currents. Detection of insulin secretion
from single 13 cells was accomplished using a sequential-cell
immunoblot method (9) whereby cells are stimulated to
secrete insulin into peptide-retentive immunoblot material
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and secreted hormone is quantified by standard densitomet-
ric methods. Details of these procedures follow.
A control strain of diabetic mouse (C57BL/KsJ-m+/+db,
"db control") and a diabetic strain (C57BL/KsJ-db+/+db,
"db/db") (the Jackson Laboratory) were used for single-cell
and islet assays. Control db mice were 6-12 weeks of age and
had an average weight of 22 g and a serum glucose of 118
mg/dl. Diabetic db/db mice of the same age weighed -50 g
and had an average serum glucose level of 374 mg/dl. For rat
islet experiments, Sprague-Dawley rats (200-250 g, Charles
River Breeding Laboratories) were used. Pancreatic islets
were selected by hand from dispersed pancreas obtained after
digestion with collagenase (0.5 mg/ml). Islets were treated
for 1 min with 0.05% trypsin and triturated to disperse them
into single cells. Cells were plated on poly(L-lysine)-coated
coverslips and cultured for 2-6 days (37°C, 5% C02/95% air)
in RPMI 1640 medium/10% (vol/vol) fetal bovine serum/2
mM L-glutamine/2.5% Nu-Serum (Collaborative Research).
Rat insulinoma (RIN-38) cells (kindly provided by W. L.
Chick and S. A. Clark, University of Massachusetts) were
maintained in medium 199/5% fetal bovine serum/1% peni-
cillin/streptomycin and used from passages 20 to 22.
Membrane voltage and whole cell currents were measured
using an Axopatch 1C amplifier (Axon Instruments, Burlin-
game, CA). Access resistance was monitored and series
resistance compensation was performed as described (10).
Currents were acquired by a 12-bit analog/digital converter
(Indec Systems, Santa Cruz, CA) and analyzed with custom
programs written in C. Data were also recorded on a pulse-
code modulated videotape recorder and analyzed with AXO-
TAPE (Axon Instruments) software. The pipette solution
contained 55 mM KCl, 95 mM potassium aspartate, 5 mM
MgCl2, 1 mM EGTA, and 20 mM Hepes, adjusted to pH 7.3.
In addition, the electrode contained nystatin (50 ug/ml),
which was freshly prepared and sonicated every 2 hr. The
bath solution was continuously perfused and contained 147
mM NaCl, 2 mM CaCl2, 5 mM KCl, 1 mM MgCl2, 5 mM
Hepes, and glucose (0-20 mM), adjusted to pH 7.4. Electro-
physiology experiments were performed at room tempera-
ture.
Rat amylin (Bachem) was stored lyophilized and used fresh
in each experiment. Except in immunoblot experiments,
amylin and bovine serum albumin (0.5 mg/ml) were dissolved
into the external recording solution immediately prior to
application to single cells via a U-tube (11). Amylin can
precipitate from solution and adheres avidly to both plastics
and glass, thus actual concentrations of the delivered peptide
are likely lower than those reported. Tolbutamide, glibencla-
mide, and diazoxide were obtained from Sigma and were also
applied to single cells via the U-tube.
Immunoblot experiments were performed using a modified
sequential cell immunoblot assay (9). Coverslips with at-
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tached cells were preincubated for 1 h at 37°C in a modified
Krebs-Ringer buffer containing 2 mM glucose. After prein-
cubation, coverslips of cells were inverted and gently placed
onto poly(vinylidine difluoride) transfer membranes (Milli-
pore) with 30 ,ul of a challenge solution separating each
coverslip and membrane. Challenge solutions contained ei-
ther glucose (2-10 mM) or glucose plus test drug. The
coverslip-membrane "sandwiches" were incubated for 1 h at
37°C, trapping secreted insulin onto the transfer membranes.
Coverslips were then gently removed from the membranes
and allowed to incubate for 1 h in control conditions. In some
experiments, coverslips were rechallenged on a second mem-
brane. Cell density was periodically checked under phase
optics during the blot sequence with subsequent fixing and
Giemsa staining to match specific cells with insulin blots and
confirm that sequential blots were in register. Serially diluted
rat insulin (Novobiolabs, Bagsvaerd, Denmark) standards
were run in parallel for each experiment. After hormone
transfer, membranes were exposed (4 h) to Tris-buffered
saline with 10% bovine serum albumin to block unoccupied
binding sites. Then, sequentially, membranes were incubated
with guinea pig anti-porcine insulin serum (1:40,000 dilution,
Novo Biolabs, 12 h), biotinylated affinity-purified anti-guinea
pig immunoglobulin (1:500 dilution, Jackson ImmunoRe-
search), and streptavidin-alkaline phosphatase conjugate
(1:3000 dilution), and then with the color reagent for 3-10
min. Control experiments replacing antiserum with normal
guinea pig serum or preabsorbing antiserum with excess
insulin eliminated insulin reactivity. Light microscopic im-
ages of immunoreactive insulin were captured with a charge-
coupled device camera (Dage-MTI) and digitally analyzed
(Image 1, Universal Imaging). Gray levels from photonega-
tive images of the insulin standards were background-
subtracted to construct a calibration curve yielding insulin in
femtograms per pixel. In some cases (e.g., see Fig. 6),
relative gray level values are reported, as all values fell in the
linear region of the calibration curve.
Insulin secretion was also measured from whole pancreatic
islets cultured for 24 h. After a preincubation in 2 mM
glucose, islets (20 islets per well) were incubated for 90 min
at 37°C in either glucose or glucose plus amylin. RIN-38 cell
insulin assays were performed on cells plated for 72 h and
then rinsed twice in modified Ringer's solution (without
serum). After preincubation in 0 mM glucose, RIN-38 cells
were challenged with glucose or glucose plus amylin at 37°C
in a humidified incubator. Insulin was measured by a scin-
tillation proximity assay using protein A-bound fluoromicro-
spheres and 125I-labeled insulin (Amersham).
RESULTS
Glucose Effects on Electrical Activity in Individual 13 Cells.
We first examined the glucose sensitivity of cells from db
control and db/db mice for comparison with responses
previously reported for ,8 cells from these and other sources.
To establish a reproducible baseline of activity, f3 cells were
equilibrated in 0-2 mM glucose for 15-45 min prior to
recordings. After equilibration, resting potentials in db con-
trol cells were -70 ± 6 mV (mean ± SD; n = 86). Elevating
glucose in the bathing solution to 5-15 mM induced a gradual
depolarization, which was followed by phasic bursts of action
potentials (Fig. 1 A and B). After this brief phasic activity,
>50% of db control cells developed a maintained depolar-
ization with continuous spike activity during exposure to the
elevated glucose (Fig. 1B). Since the majority of cells re-
sponded robustly to 8 mM glucose with phasic bursting, this
concentration was used for all subsequent comparisons.
After return to low glucose, the cells recovered their control
resting potentials (Fig. 1A).
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FIG. 1. Electrical responses of single B3cells to glucose or amylin.
Membrane potentials were recorded via nystatin-permeabilized
patches. Cells were equilibrated for 40 min in 2 mM glucose prior to
the indicated solution changes. Open bars, transitions from 2 mM to
8 mM glucose. (A) A single db control , cell responds to and recovers
from a U-tube application of 8 mM glucose. A recording gap of 8 min
is represented by the break in the trace. (B) Glucose at 8mM induced
bursting and continuous spiking in another db control cell. Amylin (5
nM, solid bar) restored phasic bursting in this cell. (C) Glucose at 8
mM was without effect in a db/db cell, which was spontaneously
active in 2 mM glucose. (D) Glucose induced depolarization and
action potentials (but no phasic bursts) in another db/db cell,
whereas amylin (500 nM, solid bar) slightly increased firing fre-
quency.
In contrast to db control 8 cells, cells from db/db mice had
resting potentials averaging -55 ± 11 mV (n = 16) in 2 mM
glucose. Approximately half of these cells generated spon-
taneous action potentials in low glucose, even after 90 min of
equilibration (Fig. 1C). Glucose induced either no effect (Fig.
1C) or a depolarization and simple increase in firing fre-
quency (Fig. 1D), rather than the bursting pattern typical of
db controls. Similar observations have been reported from
microelectrode impalements in whole intact db/db islets (12),
suggesting that neither single-cell dissociation nor perforated
patch recordings altered glucose responsiveness.
Effects of Glucose on Currents in (3 Cells. Currents under-
lying the changes in membrane potential in /3 cells were
evaluated by transiently switching from current clamp to
voltage clamp recording mode. In db control cells exposed to
low glucose (0-2 mM), a large K current that reversed
direction near the K+ equilibrium potential (EK) was revealed
by ramp command voltages (Fig. 2 A and B). This current-
voltage relationship was essentially linear between -100 and
-20 mV. Elevating external glucose (Fig. 2A) or adding
tolbutamide (Fig. 2B) reduced this current in db control cells,
consistent with observations on ATP-sensitive K (KATP)
currents in other pancreatic p cells (e.g., refs. 13 and 14).
In contrast to the db control cells, the linear component of
K current (between -100 and -20 mV) in db/db cells was
smaller in low glucose, consistent with the observed abnor-
mal membrane potentials. Moreover, glucose induced only
modest decreases in this current in db/db cells (n = 15) (Fig.
2C). The smaller current in low glucose does not reflect an
absence of KATP channels, since diaxozide (500 ,uM), which
induced membrane repolarization in db/db cells (Fig. 2D
Inset), increased the K current dramatically (Fig. 2D).
Effects of Amylin on (3 Cell Membrane Potential. After
initiation of glucose-induced action potential activity in db
control cells, the subsequent addition of amylin (0.1-500 nM)
hyperpolarized 78% (25 of 32 cells) of cells within 15-90 s.
Amylin either restored the original bursting pattern (Fig. 1B)
or completely eliminated glucose-induced action potentials
(Fig. 3A). After removal of amylin, only 60% of cells resumed
their preamylin activity; therefore, single-cell dose-response
curves were impossible to obtain. We observed, however,
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FIG. 2. Current responses of single cells to voltage-ramp
commands (-100 to +20 mV). Slope conductances (ge) were calcu-
lated between -100 and -40 mV. (A) Ramp currents in a db control
cell obtained after the switch from current clamp to voltage clamp
mode while monitoring membrane potential. Records obtained dur-
ing the application of either 2 mM glucose (gB = 1.7 nS) or 8 mM
glucose (g, = 0.51 nS) for at least 10 min. (B) Effects of tolbutamide
(30 pM; gs = 0.33 nS) on a db control , cell recorded in 0mM glucose
(g, = 3.4 nS). Same cell as in A. (Inset) Effect of tolbutamide (open
bar) on the voltage recording. (C) Ramp currents obtained from a
db/db cell after prolonged exposure to 0mM (gB = 0.65 nS) or 8mM
(gs = 0.57 nS) glucose. (D) Currents and voltage recording (Inset) in
a second db/db , cell exposed to 8 mM glucose (gs = 0.11 nS) or
glucose plus diazoxide (300 IAM, open bar, g, = 1.57 nS). Conditions
were identical for A-D, except as otherwise noted. (Insets) The
horizontal time marker represents 1 min, and vertical increments are
40 mV. All cells were 12 ,um in diameter.
that decreases in firing frequency and hyperpolarization
induced by subnanomolar concentrations of amylin were
qualitatively identical to those obtained at the highest con-
centrations tested, suggesting that amylin is effective at
extremely low concentrations.
In contrast to the results in db control cells, amylin never
hyperpolarized db/db cells. Only 2 of 16 db/db cells re-
sponded to amylin in any manner, and only then at the highest
concentrations. In 1 ofthese cells, action potential frequency
was slightly decreased, whereas in the other it was slightly
increased (Fig. 1D).
Amylin Increases Outward Currents in db Control but Not
db/db P Cells. In Fig. 3A, the current clamp recording was
interrupted at time points a-d to apply 200-ms voltage ramps.
The resulting current-voltage curves are shown in Fig. 3 B
and C. In 2 mM glucose, P cells exhibited a net outward
current (trace a) at voltages more positive than the resting
potential. Increases in external glucose, sufficient to induce
bursts of action potentials, decreased outward current be-
tween the resting potential and 0 mV, and produced a net
inward current, which peaked at approximately -10 mV
(trace b). This change in current pattern is due to a block of
KATP channels (15, 16) and increases in Ca or nonselective
cation currents (17, 18). When the cell was subsequently
exposed to amylin (despite the continued presence of ele-
vated glucose), net outward current above the resting poten-
tial was increased (trace c), as if the cell no longer sensed the
presence of glucose. Both the increase in outward current
and the accompanying hyperpolarization were reversed by
the sulfonylurea KATP channel blocker glibenclamide (trace
d). However, in each of four cells tested, the net inward
current between -20 and 0 mV was not restored by sulfo-
nylurea treatment. Only partial reversal of the amylin effects
FIG. 3. Changes in net membrane current associated with
changes in electrical activity in response to glucose, amylin, or
glibenclamide. (A) Membrane potential recorded from a db control
cell during elevation of glucose from 2 to 8 mM (open bar) and the
subsequent addition of 10 nM amylin (solid bar) and then of 1 /AM
glibenclamide (hatched bar). Membrane potential was recorded
continuously from a single cell. However, only three segments of the
recording are shown. Traces a-d indicate brief periods during which
the cell was voltage clamped and ramp commands were given to yield
the current-voltage curves shown in B and C. (B) Ramp currents in
2 mM (trace a) or 8 mM (trace b) glucose exhibiting slope conduc-
tances (ge) of 0.82 and 0.34 nS, respectively. (C) Currents in 8 mM
glucose (trace b), 10mM amylin plus 8mM glucose (trace c; g. = 0.92
nS), and glucose, amylin, and 1 ,uM glibenclamide (trace d; g, = 0.29
nS).
by sulfonylureas in this critical voltage region implies that
amylin may have effects on currents other than KATP and may
explain the failure of action potential amplitudes to com-
pletely recover in glibenclamide (Fig. 3A). Accordingly, in
some cells amylin decreased firing without increasing glib-
enclamide-sensitive currents (data not shown). In these cells,
net outward current between -30 and 0 mV was still in-
creased by the peptide. In contrast to the findings in db
control cells, amylin failed to produce any detectable changes
in net current in db/db cells (n = 14; data not shown). The
absence of changes in current is consistent with the failure of
amylin to modulate membrane potential in the diabetic cells.
Secretion from Individual P Cells Is Modulated by Sulfonyl-
ureas, Glucose, and Amylin. We sought to determine whether
changes in insulin secretion from individual control and
diabetic cells were effected under the various conditions
that altered electrical responses. We first measured insulin
secretion from individual db control cells exposed to 1 mM
glucose, with or without tolbutamide (10-50 ,uM). Consistent
with its ability to depolarize membrane potential, stimulate
action potentials, and block K currents, tolbutamide trig-
gered a dramatic increase in insulin secretion (Fig. 4). This
increase in secretion was composed primarily of increases in
the number of secreting cells, and to a lesser extent, increases
in secretion from individual cells.
In Fig. 5, three-dimensional gray scale images of sequential
immunoblots illustrate the effects of glucose or glucose plus
amylin on insulin secretion in db control or db/db cells. For
comparative purposes, secretion was quantified by integra-
tion of the gray levels over the entire field of cells in each
image. Fig. 5 A-F shows insulin blots from db control cells,
and Fig. 5 G-I is from db/db cells. Fig. 5 A, D, and G shows
basal insulin secretion when cells are exposed for 1 h to 2 mM
glucose. Consistent with the spontaneous action potential
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insulin secretion from individual db/db cells was somewhat
greater (higher peaks) than from control cells. Upon exposure
to 8 mM glucose, insulin secretion from db control ,8 cells was
markedly enhanced (compare Fig. 5 A and D with B and E),
again consistent with their robust glucose-induced electrical
activity. In contrast, despite having slightly more basal
secretion, isolated db/db cells responded only weakly to
elevated glucose (compare Fig. 5 G and H; 4-fold increase in
total secretion as compared to 22-fold for controls) consistent
with previous observations on intact db/db islets (19).
Sequential immunoblots were performed on db control (8
cells exposed first to 8 mM glucose and then to either 8 mM
glucose or glucose plus amylin (10-200 nM). The second
glucose challenge (after 1 h in 2 mM glucose) yielded a modest
27% increase in insulin secretion (Fig. 5 B and C). This
increase is consistent with the priming effect seen in pancre-
atic islets, perfused pancreases, and whole animals during
consecutive exposures to glucose (20, 21). In contrast, in six
of eight experiments in which the second glucose challenge
included amylin, the number of cells secreting insulin was
greatly reduced (Figs. 5 E and F and 6A). Consistent with
these observations, insulin secretion from intact db control
islets was also inhibited, dose-dependently, by amylin (Fig.
6A), whereas (3 cells and intact islets from db/db mice
showed nonsignificant or inconsistent changes due to amylin
(n = 4; Figs. 5 H and I and 6A).
Comparing the effects of amylin on db control cells (which
respond robustly to glucose) with those from db/db cells
(which respond poorly) suggests that the effect ofthis peptide
is restricted to those cells with normal glucose-sensing. We
further tested this hypothesis by assessing amylin actions on
the electrical and secretory responses of other cells with
normal (rat (3 cells or islets) or abnormal (RIN-38) glucose
sensing. Sprague-Dawley rat p cells and islets have been
shown by many groups to have vigorous electrical and
secretory responses to variations in glucose between 2 and 15
mM. In rat islets, amylin significantly decreased insulin
secretion (Fig. 6B). In contrast, RIN-38 cells have abnormal
insulin response patterns with no glucose dependency above
0.5 mM glucose (22). Consistent with this abnormal secretory
pattern, in zero glucose, their average resting potential was
-50 ± 10 mV (n = 18) and they frequently exhibited
spontaneous action potentials. These cells did not show a
FIG. 5. Three-dimensional representations of immunoreactive
insulin secreted from single ,B cells. In some cases the image field
represents a sequential determination of secretion from the same
cells, but in all cases the density of cells is equivalent. The maximum
gray level (lightest tone) corresponds to 45 fg ofinsulin per pixel. The
total integrated gray level was determined for each image field (all
cells) as a relative measure of insulin secretion and is given in units
of gray level (x 106). Cell types, solutions, and secretion (gray level
units) are as follows. (A) db control, 2 mM glucose, 0.116. (B) db
control, 8 mM glucose, 2.705. (C) Sequential assay of B, 8 mM
glucose, 3.437. (D) db control, 2 mM glucose, 0.113. (E) db control,
8 mM glucose, 1.778. (F) Sequential assay of E, 8 mM glucose plus
100 nM amylin, 0.47. (G) db/db, 2 mM glucose, 0.498. (H) db/db,
8 mM glucose, 1.69. (I) Sequential assay ofH, 8 mM glucose plus 100
nM amylin, 1.46. (Bar = 100 ,um.)
consistent electrical response to glucose nor a bursting elec-
trical pattern. As hypothesized, in these cells, amylin, at
concentrations up to 500 nM, rarely reduced the firing rate (1











~A =oL db * _ db/db
LA0I





0 1 10 0 1 10
Amylin, nM Amylin, nM
FIG. 4. Pseudocolor representations of insulin secretion (by
sequential-cell immunoblot assay) from single cells of db control
mice. Insulin immunoblots were from separate coverslips incubated
for 1 h in either 1 mM glucose (Left) or 1 mM glucose plus 50 LM
tolbutamide (Right). Calibrated levels of insulin range from 1.8 fg per
pixel (light blue) to 95 fg per pixel (white).
FIG. 6. Effects of amylin on insulin secretion. (A) Insulin secre-
tion vs. amylin concentration for db control or db/db islets as
determined by scintillation proximity assay (bars; n = 4 each, mean
± SD). For comparison, the total integrated gray levels from the
immunoblots (Fig. 5 E, F, H, and I) are shown (circles). For both
measurements, effects of amylin are not dose-related in db/db cells
as compared to db control cells (P c 0.05 for amylin concentrations
>10 nM for db control cells). (B) Effects of amylin on insulin
secretion from rat islets exposed to 8 mM glucose. (C) Effects of
amylin on insulin secretion from RIN-38 cells exposed to 0.5 mM
glucose. Insulin secretion in B and C was determined by scintillation
proximity assay (mean ± SEM, n = 3).
0
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DISCUSSION
The pancreatic , cell of the control db mouse exhibits an
electrical response to extracellular glucose that is qualita-
tively similar to that of (3 cells from many other sources. In
contrast, cells isolated from the diabetic db/db mouse strain
exhibit abnormal electrical activity and glucose responsive-
ness (ref. 12 and present study). The insulin secretory re-
sponses of these two (-cell types correlate well with their
respective electrophysiological behavior. It is intriguing that
cells with normal glucose responses (db control mice and
Sprague-Dawley rats) also exhibit an amylin response,
whereas cells with abnormal glucose responses (db/db mice
and RIN-38 cells) are insensitive to amylin.
Amylin appears to act in part through an increase in
glibenclamide-sensitive K current. It is unlikely that amylin
directly modulates KATP channel activity but, rather, alters
the 13 cell's ability to sense or metabolize glucose and, in turn,
regulate KATP channel activity. This is suggested by the long
delay (15-90 s) for full expression of the channel effects
(perhaps reflecting an essential metabolic step) and the
absence of effects in whole-cell dialysis experiments as
compared to perforated patch recordings (data not shown).
Furthermore, since both normal and abnormal cells appar-
ently express KATP channels, the poor sensitivity of db/db
and RIN-38 cells to glucose and amylin does not reflect an
absence of this requisite channel target. Recently, glucose
transporter Glut2 expression has been shown to be decreased
in , cells from db/db mice (23). It is possible that loss of this
transporter and loss of amylin responsiveness are related.
Amylin, by decreasing but not eliminating the 83 cell's
capacity for electrical activity, may serve a protective func-
tion. As ,Bcells are exposed to variations in circulating glucose
levels and respond with variations in insulin secretion, co-
secreted amylin may limit prolonged depolarization and con-
stantly elevated intracellular Ca2 , thus modulating the phasic
electrical, Ca2+, and insulin bursts. In the normal pancreas,
amylin may act in concert with other peptides or hormones to
establish the set point for glucose sensing. In the diabetic
pancreas, as the 8 cell loses its glucose sensing capability, it
may coincidentally lose its ability to respond to amylin. In
advanced type II diabetes, local amylin excesses (24) could
further contribute to the inability of the ,B cell to accurately
sense and respond to normal variations in glucose levels.
Although it is impossible to precisely measure the local
concentration of amylin as it is secreted from the 3 cell, local
concentrations up to 10-8 M have been estimated (25, 26).
Effects seen in this study were robust at this concentration, as
well as at lower and higher concentrations (0.1-500 nM).
Galanin and somatostatin also suppress insulin release.
Furthermore, these peptides also act at least in part via a
repolarization-induced reduction in intracellular Ca2+. These
effects are believed to be due to opening of KATP channels or
to direct interactions with guanine nucleotide binding proteins
coupled to ion channels or to exocytotic machinery (13, 27).
Similarly, calcitonin-gene-related peptide (CGRP), which
shares 46% sequence homology with amylin and modulates K
and Ca currents in muscle and nerve (28-31), reduces insulin
secretion from both single rat (8 cells and islets (32, 33).
Although it is possible that local (3cell effects of amylin are
mediated through low-affinity CGRP receptors (34), both
amylin secretion from the , cell and its link to type II diabetes
make it unique among peptide and hormone modulators of the
l3 cell (35, 36). Unlike other peptides that are either released
from nerve terminals in the endocrine pancreas or from other
pancreatic cell types, amylin is cosecreted with insulin from
the cell in response to glucose. Amylin release is, therefore,
modulated by the stimulus that it may ultimately play a role in
regulating. Nonetheless, it will be of interest to investigate this
entire family of peptides, including calcitonin and CGRP, as to
their regulation of specific ,(3cell ion channels, comparing their
affinities and potencies, and identifying the points at which
they may interact with the glucose-sensing mechanism of the
pancreatic 8 cell.
We thank V. Montana for preparation of , cells; M. Lancaster and
R. Mertz for islet and RIN-38 SPAs; and S. Lassiter for assistance
with the sequential-cell immunoblot assays. This research was
supported by Glaxo Research Institute (P.K.W., C.C., J.F.W., and
I.D.D.) and by National Institutes of Health Grant NS18788 (G.S.O).
1. Ahren, B., Arkhammar, P., Berggren, P.-O. & Nilsson, T. (1986)
Biochem. Biophys. Res. Commun. 140, 1059-1063.
2. Lukinius, A., Wilander, E., Westermark, G. T., Engstrom, U. &
Westermark, P. (1989) Diabetologia 32, 240-244.
3. Cooper, G. J. S., Willis, A. C., Clark, A., Turner, R. C., Sim, R. B.
& Reid, K. B. (1987) Proc. Natl. Acad. Sci. USA 84, 8628-8632.
4. Ohsawa, H., Kanatsuka, A., Yamaguchi, T., Makino, H. &
Yoshida, S. (1989) Biochem. Biophys. Res. Commun. 160, 961-967.
5. Suzuki, S., Murakami, M., Abe, S., Satoh, Y., Shintani, S.,
Ishizuka, J., Suzuki, K.-I., Thompson, J. C. & Toyota, T. (1992)
Diabetes Res. Clin. Pract. 15, 77-84.
6. Silvestre, R. A., Peir6, E., Degano, P., Miralies, P. & Marco, J.
(1990) Regul. Pept. 31, 23-31.
7. Nagamatsu, S., Nishi, M. & Steiner, D. F. (1992) Diabetes Res.
Clin. Prac. 15, 49-56.
8. Horn, R. & Marty, A. (1988) J. Gen. Physiol. 92, 145-159.
9. Arita, J., Kohima, Y. & Kimura, F. (1991) Endocrinology 128,
1887-1894.
10. Sala, S., Parsey, R. V., Cohen, A. S. & Matteson, D. R. (1991) J.
Membr. Biol. 122, 177-187.
11. Oxford, G. S. & Wagoner, P. K. (1989) J. Physiol. (London) 410,
587-612.
12. Meissner, H. P. & Schmidt, H. (1976) FEBS Lett. 67, 371-374.
13. de Weille, J., Schmid-Antomarchi, H., Fosset, M. & Lazdunski, M.
(1988) Proc. Natl. Acad. Sci. USA 85, 1312-1316.
14. Ashcroft, S. J. & Ashcroft, F. M. (1990) Cell Signalling 2, 197-214.
15. Ashcroft, F. M., Ashcroft, S. J. H. & Harrison, D. E. (1988) J.
Physiol. (London) 400, 501-527.
16. Smith, P. A., Ashcroft, F. M. & Rorsman, P. (1990) FEBS Lett.
261, 187-190.
17. Smith, P. A., Rorsman, P. & Ashcroft, F. M. (1989) Nature (Lon-
don) 342, 550-553.
18. Rojas, E., Hidalgo, J., Carroll, P. B. & Atwater, I. (1990) FEBS
Lett. 261, 265-270.
19. Boquist, L., Hellman, B., Lernmark, A. & Taljedal, I.-B. (1974) J.
Cell Biol. 62, 77-89.
20. Grodsky, G. & Heldt, H. (1984) in Methods in Diabetic Research:
Vol. 1, Laboratory Methods, eds. Lamer, J. & Pohl, S. (Wiley, New
York), Part B, pp. 137-147.
21. Rasmussen, H., Zawalich, K., Ganesan, S., Calle, R. & Zawalich,
W. (1990) Diabetes Care 13, 655-666.
22. Clark, S. A., Burnham, B. L. & Chick, W. L. (1990) Endocrinology
127, 2779-2788.
23. Thorens, B., Wu, Y. J., Leahy, J. L. & Weir, G. C. (1992) J. Clin.
Invest. 90, 77-85.
24. Tokuyama, Y., Kanatsuka, A., Ohsawa, H., Yamaguchi, T.,
Makino, H., Yoshida, S., Hagase, H. & Inoue, S. (1992) Diabetes
Res. Clin. Pract. 15, 23-29.
25. Kanatsuka, A., Makino, H., Ohsawa, H., Tokuyama, Y., Yama-
guchi, T., Yoshida, S. & Adachi, M. (1989) J. Biol. Chem. 265,
4173-4177.
26. Nagamatsu, S., Carroll, R. J., Grodsky, G. M. & Steiner, D. F.
(1990) Diabetes 39, 871-874.
27. Nilsson, T., Arkhammar, P., Rorsman, P. & Berggren, P.-O. (1989)
J. Biol. Chem. 264, 973-980.
28. Ono, K. & Giles, W. R. (1991) J. Physiol. (London) 436, 195-217.
29. Kim, D. (1991) Pfliugers Arch. 418, 338-345.
30. Nelson, M. T., Huang, Y., Brayden, J. E., Hescheler, J. &
Standen, N. B. (1990) Nature (London) 344, 770-773.
31. Zona, C., Farini, D., Palma, E. & Eusebi, F. (1991) J. Physiol.
(London) 433, 631-643.
32. Lewis, C. E., Clark, A., Ashcroft, S. J. H., Cooper, G. J. S. &
Morris, J. F. (1988) Mol. Cell. Endocrinol. 57, 41-49.
33. Pettersson, M. & Ahren, B. (1990) Diabetes Res. 15, 9-14.
34. Galeazza, M. T., O'Brien, T. D., Johnson, K. H. & Seybold, V. S.
(1991) Peptides 12, 585-591.
35. Nishi, M., Sanke, T., Nagamatsu, S., Bell, G. I. & Steiner, D. F.
(1990) J. Biol. Chem. 265, 4173-4176.
36. Johnson, K. H., O'Brien, T. D., Betsholtz, C. & Westermark, P.
(1992) Lab. Invest. 66, 522-535.
Physiology: Wagoner et al.
